Healthcare
Hisamitsu Pharmaceutical Co., Inc.(HTSUY)
Live Price
Offline$2.94
+0.00% today
Window Change
-35.38%
Window
May 12, 2026 โ Jun 23, 2026
- Market Cap
- $2.64B
- Revenue Growth
- +6.3%
- EPS Growth
- -6.3%
- Dividend Yield
- 0.6%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 29 bars ยท May 12, 2026 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hisamitsu Pharmaceutical Co., Inc. (HTSUY) is a Healthcare stock with a market cap of $2.64B and listed on OTC. The stock last traded around $2.94 and down 35.4% across the available one-year price window (May 12, 2026 โ Jun 23, 2026). Baseline metrics include revenue growth of +6.3%, EPS growth of -6.3%, a dividend yield of 0.6%. What stands out right now is revenue +6.3%, EPS -6.3%, free cash flow +87.8% with operating margin 11.0% and ROIC 4.8%. The dividend is present but secondary, with a yield around 0.6%. Valuation is more restrained than many high-expectation growth names at P/E 21.0 and price/sales 2.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HTSUY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.3% vs +7.6% peer median
Operating Margin
Below sector median
+11.0% vs +19.4% peer median
P/E
Below sector median
21.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.3% and EPS is at -6.3%, with operating margin around 11.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
HTSUY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HTSUY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HTSUY Max Drawdown
-55.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HTSUY and SPY.
Company Overview
Hisamitsu Pharmaceutical Co., Inc.
Other OTC
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
- Leadership
- Kazuhide Nakatomi
- IPO Date
- Sep 6, 2017
- Employees
- 2.8k
- Street Address
- 408 Tashirodaikan-machi
- Mailing
- Tosu, 841-0017
- Region
- Tosu, JP
- Reporting Currency
- USD
- Investor Line
- +81 3 5293 1700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.0
- EV/EBITDA
- 11.8
- Price/Sales
- 2.4
- Price/Book
- 1.4
Growth
- Revenue
- +6.3%
- EPS
- -6.3%
- Free Cash Flow
- +87.8%
Profitability
- Gross Margin
- 59.0%
- Operating Margin
- 11.0%
- Net Margin
- 11.7%
- ROE
- 7.0%
- ROIC
- 4.8%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 4.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.